Webcast Alert: Aastrom to Host Third Quarter 2011 Investor Call on Tuesday, November 8, 2011
31. Oktober 2011 16:05 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 31, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Appoints Brian Gibson as Vice President, Finance
13. Oktober 2011 16:05 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Granted European Composition-of-Matter Patent for Ixmyelocel-T
03. Oktober 2011 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 3, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Present at the Sixth Annual JMP Securities Healthcare Conference
23. September 2011 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 23, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Announces Positive 12-Month Safety and Efficacy Data From IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy
19. September 2011 09:00 ET
|
Aastrom Biosciences, Inc.
Results presented today at 15th Annual Heart Failure Society of America Scientific Meeting
Aastrom also announces results of six-month interim analysis of DCM patients
treated with ixmyelocel-T...
Aastrom Chief Scientific Officer Ronnda Bartel, PhD, to Present at the Cell Therapy Commercialization Summit
16. September 2011 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 16, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Present 12-Month Data From the IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy
14. September 2011 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 14, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Present at the 13th Annual Rodman & Renshaw Healthcare Conference
08. September 2011 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 8, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Present at the Stifel Nicolaus Healthcare Conference
01. September 2011 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Operating Results for the Quarter and Six Months Ended June 30, 2011
15. August 2011 16:01 ET
|
Aastrom Biosciences, Inc.
Phase 3 REVIVE-CLI clinical trial to begin next quarter
Final Phase 2b CLI data presentation at AHA meeting in November
Final Phase 2 DCM data presentation at HFSA meeting next month...